Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Celyad OncologyCLYYF +40.00%28 Buyback Yield % is -8.42 as of Aug. 11, 2026. GuruFocus rates CLYYF with a GF Score™ of 28/100. The stock has 6 warning signs investors should review. Among 725 Biotechnology companies, Celyad Oncology ranks better than 52.83% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Celyad Oncology's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLYYF vs VRTX, REGN, RVMD: Buyback Yield % Comparison
For the Biotechnology subindustry, Celyad Oncology's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celyad Oncology Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celyad Oncology's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Celyad Oncology's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celyad Oncology (CLYYF) has a Buyback Yield % of -8.42 as of Aug. 11, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Celyad Oncology and its competitors. According to the industry distribution chart, Celyad Oncology ranks #342 out of 725 companies in the Biotechnology industry, placing it in the top 47.2%.
Is Celyad Oncology's Buyback Yield % too high?
Celyad Oncology's current Buyback Yield % is -8.42. Based on the distribution chart, Celyad Oncology ranks #342 out of 725 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Celyad Oncology has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Celyad Oncology ranks #342 out of 725 companies for Buyback Yield %. This puts Celyad Oncology in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Celyad Oncology and its competitors. Celyad Oncology's current Buyback Yield % is -8.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Celyad Oncology (CLYYF) has a current Buyback Yield % of -8.42. The current Buyback Yield % is -8.42. Celyad Oncology's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Celyad Oncology (CLYYF), the current Buyback Yield % is -8.42 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
28GF Score
Get the complete analysis for CLYYF
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLYYF has been successfully added to your 
